Terms: = Endocrine gland cancer AND TRA AND Treatment
29 results:
1. Pharmacokinetics/Pharmacodynamics of Dabrafenib and trametinib for Redifferentiation and treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid cancer.
Balakirouchenane D; Seban R; Groussin L; Puszkiel A; Cottereau AS; Clerc J; Vidal M; Goldwasser F; Arrondeau J; Blanchet B; Huillard O
Thyroid; 2023 Nov; 33(11):1327-1338. PubMed ID: 37725566
[No Abstract] [Full Text] [Related]
2. A targetable pathway to eliminate tra-1-60+/tra-1-81+ chemoresistant cancer cells.
Tan L; Duan X; Mutyala P; Zhou T; Amin S; Zhang T; Herbst B; Askan G; Itkin T; Xiang Z; Michelassi F; Lieberman MD; Iacobuzio-Donahue CA; Leach SD; Evans T; Chen S
J Mol Cell Biol; 2023 Nov; 15(6):. PubMed ID: 37327088
[TBL] [Abstract] [Full Text] [Related]
3. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
[TBL] [Abstract] [Full Text] [Related]
4. HER-2-mediated nano-delivery of molecular targeted drug potently suppresses orthotopic epithelial ovarian cancer and metastasis.
Wang Z; Guo B; Yue S; Zhao S; Meng F; Zhong Z
Int J Pharm; 2022 Sep; 625():122126. PubMed ID: 35995316
[TBL] [Abstract] [Full Text] [Related]
5. HER2-Specific Reduction-Sensitive Immunopolymersomes with High Loading of Epirubicin for Targeted treatment of Ovarian Tumor.
Ding L; Gu W; Zhang Y; Yue S; Sun H; Cornelissen JJLM; Zhong Z
Biomacromolecules; 2019 Oct; 20(10):3855-3863. PubMed ID: 31513391
[TBL] [Abstract] [Full Text] [Related]
6. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract] [Full Text] [Related]
7. The novel traIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells.
Legler K; Hauser C; Egberts JH; Willms A; Heneweer C; Boretius S; Röcken C; Glüer CC; Becker T; Kluge M; Hill O; Gieffers C; Fricke H; Kalthoff H; Lemke J; Trauzold A
Cell Death Dis; 2018 May; 9(5):445. PubMed ID: 29670075
[TBL] [Abstract] [Full Text] [Related]
8. The CA19-9 and Sialyl-tra Antigens Define Separate Subpopulations of Pancreatic cancer Cells.
Barnett D; Liu Y; Partyka K; Huang Y; Tang H; Hostetter G; Brand RE; Singhi AD; Drake RR; Haab BB
Sci Rep; 2017 Jun; 7(1):4020. PubMed ID: 28642461
[TBL] [Abstract] [Full Text] [Related]
9. Thyroid Patient Salivary Radioiodine transit and Dysfunction Assessment Using Chewing Gums.
Okkalides D
Cancer Biother Radiopharm; 2016 Nov; 31(9):330-341. PubMed ID: 27831763
[TBL] [Abstract] [Full Text] [Related]
10. The Result of Multiple I-131 treatments on the Effective Half-Life of Retained Radioactivity in Patients Ablated for Differentiated Thyroid cancer: Possible Evidence for Thyroid Remnant Function Impairment.
Okkalides D
Cancer Biother Radiopharm; 2016 Mar; 31(2):58-64. PubMed ID: 26986816
[TBL] [Abstract] [Full Text] [Related]
11. A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of tra-8/DR5 Oligomers Predicts tra-8 Therapeutic Efficacy in Breast and Pancreatic cancer Mouse Models.
Kim H; Buchsbaum DJ; Zinn KR
Mol Imaging Biol; 2016 Jun; 18(3):325-33. PubMed ID: 26552657
[TBL] [Abstract] [Full Text] [Related]
12. Calmodulin antagonists promote tra-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract] [Full Text] [Related]
13. Thyroid remnant ablation in differentiated thyroid cancer: searching for the most effective radioiodine activity and stimulation strategy in a real-life scenario.
Campennì A; Giovanella L; Pignata SA; Violi MA; Siracusa M; Alibrandi A; Moleti M; Amato E; Ruggeri RM; Vermiglio F; Baldari S
Nucl Med Commun; 2015 Nov; 36(11):1100-6. PubMed ID: 26302462
[TBL] [Abstract] [Full Text] [Related]
14. Near infrared photoimmunotherapy in the treatment of disseminated peritoneal ovarian cancer.
Sato K; Hanaoka H; Watanabe R; Nakajima T; Choyke PL; Kobayashi H
Mol Cancer Ther; 2015 Jan; 14(1):141-50. PubMed ID: 25416790
[TBL] [Abstract] [Full Text] [Related]
15. Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Forero-Torres A; Infante JR; Waterhouse D; Wong L; Vickers S; Arrowsmith E; He AR; Hart L; Trent D; Wade J; Jin X; Wang Q; Austin T; Rosen M; Beckman R; von Roemeling R; Greenberg J; Saleh M
Cancer Med; 2013 Dec; 2(6):925-32. PubMed ID: 24403266
[TBL] [Abstract] [Full Text] [Related]
16. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.
Welsh L; Powell C; Pratt B; Harrington K; Nutting C; Harmer C; Newbold K
J Clin Endocrinol Metab; 2013 May; 98(5):1819-25. PubMed ID: 23493434
[TBL] [Abstract] [Full Text] [Related]
17. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract] [Full Text] [Related]
18. Recurrent seminomas: clinical features and biologic implications.
Som A; Zhu R; Guo CC; Efstathiou E; Xiao L; Pisters LL; Matin A; Tu SM
Urol Oncol; 2012; 30(4):494-501. PubMed ID: 20822932
[TBL] [Abstract] [Full Text] [Related]
19. Effect of tra-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
Frederick PJ; Kendrick JE; Straughn JM; Della Manna DL; Oliver PG; Lin HY; Grizzle WE; Stockard CR; Alvarez RD; Zhou T; LoBuglio AF; Buchsbaum DJ
Int J Gynecol Cancer; 2009 Jul; 19(5):814-9. PubMed ID: 19574765
[TBL] [Abstract] [Full Text] [Related]
20. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Kim H; Morgan DE; Buchsbaum DJ; Zeng H; Grizzle WE; Warram JM; Stockard CR; McNally LR; Long JW; Sellers JC; Forero A; Zinn KR
Cancer Res; 2008 Oct; 68(20):8369-76. PubMed ID: 18922909
[TBL] [Abstract] [Full Text] [Related]
[Next]